Balyasny Asset Management’s Ascendis Pharma A/S ASND Stock Holding History

Balyasny Asset Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-24,079	Closed	-$5.13M	–	2874
2025 Q4	$5.13M	Buy	+24,079	New	+$4.97M	0.01%	1379
2025 Q1	–	Sell	-15,419	Closed	-$2.12M	–	2776
2024 Q4	$2.12M	Buy	+15,419	New	+$2.03M	﹤0.01%	1652
2024 Q3	–	Sell	-4,221	Closed	-$576K	–	2727
2024 Q2	$576K	Buy	+4,221	New	+$574K	﹤0.01%	2005
2023 Q4	–	Sell	-94,868	Closed	-$8.88M	–	2482
2023 Q3	$8.88M	Buy	+94,868	New	+$8.88M	0.02%	892
2023 Q2	–	Sell	-13,394	Closed	-$1.44M	–	2258
2023 Q1	$1.44M	Sell	13,394 -40,103	-75%	-$4.59M	﹤0.01%	1599
2022 Q4	$6.53M	Buy	+53,497	New	+$6.21M	0.02%	916

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Balyasny Asset Management's ASND Position: Q1 2026 in Review

Balyasny Asset Management sold out of Ascendis Pharma A/S (ASND) in Q1 2026, closing a stake of 24,079 shares — an estimated $5.13M sold.

Balyasny Asset Management first reported a position in ASND in Q4 2022 and held it in 6 quarters. The position peaked at $8.88M in Q3 2023. 273 funds tracked by Wall St. Rank hold ASND as of Q1 2026.

Balyasny Asset Management reported no remaining Ascendis Pharma A/S position as of Q1 2026 after selling out during the quarter.
Balyasny Asset Management sold 24,079 Ascendis Pharma A/S shares in Q1 2026, an estimated $5.13M.
Balyasny Asset Management first reported a position in Ascendis Pharma A/S in Q4 2022 and held it in 6 quarters.
Balyasny Asset Management's Ascendis Pharma A/S position peaked at $8.88M in Q3 2023.
273 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.